Please login to the form below
Healthcare terms - P
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare terms - P
- Packaging
- Pandemic
- Parallel importing
- Pareto principle
- Patent
- Payback period
- Payment by results (PBR)
- Peer review
- Peer to peer (P2P) marketing
- PEEST
- Penetrated market
- Penetration pricing
- Perfect competition
- Performance prism
- Persistence
- Personal data
- Personal selling
- PESTLE
- Pharmaceutical Pricing Regulation Scheme (PPRS)
- Pharmaceutical Researchers and Manufacturers of America (PhRMA)
- Pharmacokinetics
- Pharmacy Benefit Manager (PBM)
- Phase I trials
- Phase II trials
- Phase III trials
- Phase IV trials
- Pilot programme
- Placebo
- Placebo effect
- Placebo-controlled trial
- Point of sale (POS)
- Point-of-purchase displays
- Porter's 'Five Forces'
- Portfolio
- Portfolio analysis
- Positioning
- Post detail survey
- Post-testing
- Practice Based Commissioning (PBC)
- Pre-clinical trials
- Preferred provider organisation (PPO)
- Premium pricing
- Prescribing Analysis and Cost (PACT)
- Prescribing information
- Prescription Medicines Code of Practice Authority (PMCPA)
- Prescription only medicine (POM)
- Press release
- Prevention trials
- Price fixing
- Price maker
- Price taker
- Primary care
- Primary Care Trust (PCT)
- Prior approval
- Procurement officer/manager
- Product attributes
- Product class
- Product differentiation
- Product pipeline
- Promotional mix
- Promotional plan
- Prompted recall
- Prophylaxis
- Proprietary name
- Protocol
- Public relations
- Publication planning
- Publics
- Pull promotion
- Purchasing power parities (PPP)
- Push promotion
- “P” Medicine
COVID-19 Updates and Daily News
Featured jobs
- Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’
- Relief Therapeutics’ COVID-19 drug shows positive results ahead of trial readout
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- Novartis weathers the COVID-19 storm in Q3, lifts outlook
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- UK Vaccine Taskforce chief says first COVID-19 vaccines ‘likely to be imperfect’
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Quick links
Infographics
